Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

ArQule (ARQL - Snapshot Report) continues to focus its efforts on developing lead candidate tivantinib (ARQ 197) after having suffered a few setbacks earlier in the year.

We note that ArQule is developing tivantinib in collaboration with Japanese company Daiichi Sankyo. ArQule currently does not have any marketed product in its portfolio and tivantinib is its most advanced stage candidate, which is being developed for a variety of indications.

ArQule presented encouraging data from a randomized, double-blind, placebo-controlled phase III trial, MARQUEE, at the European Cancer Congress.

The data showed the clinical benefits of treatment with the combination of tivantinib and Roche’s (RHHBY - Analyst Report) Tarceva (erlotinib) in patients suffering from non-squamous, non-small cell lung cancer (NSCLC) whose tumors expressed high levels of MET protein.

The final analysis of data from the MARQUEE trial showed tivantinib was significantly effective in treating MET High NSCLC patients and showed improvements in both overall survival (OS) and progression free survival (PFS).

However, patients with MET Low NSCLC did not experience significantly improved OS despite their increased PFS.

We remind investors that ArQule suffered a setback when the MARQUEE trial was stopped in Oct 2012 after a planned interim analysis. The independent Data Monitoring Committee (DMC) had recommended that the study should be discontinued as it was not likely to meet its primary endpoint of improved overall survival. 

Subsequently, the trial was allowed to be continued in patients, whose disease had not yet progressed after the interim analysis. The data cut-off for full study analysis was Dec 15, 2012.

Although the trial has been stopped, ArQule and Daiichi Sankyo will consider the full analysis of data from the MARQUEE trial and other studies and thereafter decide on the further development of tivantinib for the NSCLC indication or in certain biomarker-defined sub-groups within the diseased population.

Meanwhile, ArQule is also evaluating tivantinib for the treatment of hepatocellular cancer.

We expect investor focus to remain on further updates on tivantinib from the different trials being conducted.

ArQule currently carries a Zacks Rank #3 (Hold). Right now, Jazz Pharmaceuticals (JAZZ - Analyst Report) and Cempra, Inc. (CEMP - Snapshot Report) look attractive. While Jazz Pharma carries a Zacks Rank #1 (Strong Buy), Cempra carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%